Entelexo Biotherapeutics

Creating a New Class of Drugs to Address Incurable Autoimmune Diseases

Y CombinatorWinter 2021ActiveHealthcareTherapeuticsBiotech

What they do

Problem

Patients with immune-mediated autoimmune diseases like psoriasis lack effective, modern treatments for conditions that can be difficult or impossible to cure.

Solution

The company develops novel engineered exosome-based therapeutics to treat immune-mediated diseases.

Who it's for

Clinicians and healthcare systems treating patients with autoimmune and immune-mediated diseases.

Founders

MILAD RIAZIFAR

Founder

Dr. Riazifar has worked on stem cells over a decade and on exosomes a subclass of stem cell derived extracellular vesicles since 2012. During his Ph.D studies at the Stem Cell Research Center at the University of California Irvine, he pioneered a cell-free exosome-based approach to treat Multiple Sclerosis. At City of Hope, he was part of a clinical translation team initiating the world’s first clinical trial using stem cell exosomes for the treatment of type I diabetes.

Todd Schurr

Founder

Multidisciplinary engineer with diverse experience in cellular biology, electrical engineering, automotive, and more. To quote Einstein, I am "passionately curious" regarding just about everything.